Induction chemotherapy in head and neck squamous cell carcinoma of the paranasal sinus and nasal cavity: a role in organ preservation.
- Author:
Chan Young OCK
1
;
Bhumsuk KEAM
;
Tae Min KIM
;
Doo Hee HAN
;
Tae Bin WON
;
Se Hoon LEE
;
J Hun HAH
;
Tack Kyun KWON
;
Dong Wan KIM
;
Dong Young KIM
;
Chae Seo RHEE
;
Hong Gyun WU
;
Myung Whun SUNG
;
Dae Seog HEO
Author Information
- Publication Type:Original Article
- Keywords: Induction chemotherapy; Head and neck neoplasms; Paranasal sinuses; Nasal cavity; Orbit evisceration
- MeSH: Carcinoma, Squamous Cell*; Cisplatin; Disease Progression; Drug Therapy; Fluorouracil; Head and Neck Neoplasms; Head*; Humans; Induction Chemotherapy*; Nasal Cavity*; Neck*; Orbit; Orbit Evisceration; Organ Preservation*; Paranasal Sinuses
- From:The Korean Journal of Internal Medicine 2016;31(3):570-578
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND/AIMS: The role of induction chemotherapy (IC) for eyeball preservation has not been established in head and neck squamous cell carcinoma (HNSCC) of the paranasal sinus and nasal cavity (PNSNC). Periorbital involvement frequently leads to eyeball exenteration with a margin of safety. We evaluated the treatment outcomes, including survival and eyeball preservation, of patients who received IC for HNSCC of the PNSNC. METHODS: We reviewed 21 patients diagnosed with HNSCC of the PNSNC who were treated with IC. We analyzed response, eyeball preservation rate, and overall survival. RESULTS: Tumors were located in the paranasal sinus (n = 14) or nasal cavity (n = 7). Most patients had stage T4a (n = 10) or T4b (n = 7) disease. More than half of the patients received a chemotherapy regimen of docetaxel, fluorouracil, and cisplatin (n = 11). Thirteen patients (61.9%) achieved a partial response after IC and 15 patients (71.4%) achieved T down-staging. Among 17 patients with stage T4 disease, which confers a high risk of orbital exenteration, 14 (82.4%) achieved preservation of the involved eye. The 3-year overall survival (OS) rate of patients who achieved a partial response to IC was 84.6%. The 3-year OS rate of patients with stable disease or disease progression after IC was 25.0% (p = 0.038). CONCLUSIONS: IC could be considered for down-staging patients with advanced T-stage disease. It could also be a reasonable option for eyeball preservation in locally advanced HNSCC of the PNSNC.
